Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 3M COMMM · Entity 1275 | EVP & Chief Info Digital Off | February 02, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
3M CO
Report date February 02, 2026 · Filed February 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,024.9451 |
Reported balance
After 2026-02-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-02-02 · Tax withholding · Disposed 4,793.011 · Balance 13,024.9451 F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 7,136 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 4,200 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 8,448 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 16,840 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 19,616 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-01-04 · Disposition to issuer · Disposed 23,936 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.99 · Expires 2021-04-26 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 13,460 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 1,295 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 625 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-01-04 · Disposition to issuer · Disposed 1,114 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-01-04 · Disposition to issuer · Disposed 1,905 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 9, 2026 21:21 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionRestricted Stock Units · Derivative | 8,895 | $0.00 | $0.00 |
DisclosureSEC source: 0000066740-26-000058 · form4.xml · derivative · entry 3 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F3 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date of February 7, 2023. F3 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date of February 7, 2023. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 21:21 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 3,238 | $172.65 | $559,040.70 |
DisclosureSEC source: 0000066740-26-000058 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,871.9561 F1 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 21:21 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 8,895 | $172.65 | $1,535,721.75 |
DisclosureSEC source: 0000066740-26-000058 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,109.9561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:07 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,619 | $0.00 Strike: $172.65 | $0.00 |
DisclosureSEC source: 0000066740-26-000101 · form4.xml · derivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,619 Underlying: Common Stock · 12,619 shares Expires 2036-02-05 F3 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:07 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 2,915 | $0.00 | $0.00 |
DisclosureSEC source: 0000066740-26-000101 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,915 Underlying: Common Stock · 2,915 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F2 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date. F2 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:06 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 603 | $0.00 | $0.00 |
DisclosureSEC source: 0000066740-26-000026 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,214.9561 F2 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary. F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:06 UTC | 3M CO MMM · Entity 1275 | GrantCommon Stock | 11,173.408 | $0.00 | $0.00 |
DisclosureSEC source: 0000066740-26-000026 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,817.9561 F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 1, 2023. The performance-based vesting requirements applicable to such awards were satisfied on the date reported in Column 2 above, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of ninety-three percent of the shares and will not have voting or investment powers with respect to such shares until they are issued. Read SEC document |
| February 02, 2026 Filed Feb 18, 2026 21:12 UTC Amendment | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 4,793.011 | $0.00 | $0.00 |
DisclosureSEC source: 0000066740-26-000128 · form4a.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,024.9451 F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 19,061 | $0.00 Strike: $142.94 | $0.00 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · derivative · entry 22 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,061 shares Expires 2032-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 350 | $166.75 | $58,362.50 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 21 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,594.1875 F1 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1 | $166.73 | $166.73 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 20 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,944.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1 | $166.68 | $166.68 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 19 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,945.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 104 | $166.67 | $17,333.68 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 18 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,946.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1,701 | $166.66 | $283,488.66 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 17 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,050.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 7 | $166.65 | $1,166.55 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 16 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,751.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 12 | $166.63 | $1,999.56 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 15 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,758.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1,700 | $166.63 | $283,262.50 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 14 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,770.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 122 | $166.62 | $20,327.64 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 13 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,470.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 10 | $166.59 | $1,665.90 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 12 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,592.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 623 | $166.58 | $103,779.34 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 11 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,602.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 260 | $166.57 | $43,308.20 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 10 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,225.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1,466 | $166.56 | $244,176.96 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 9 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,485.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 765 | $166.55 | $127,410.75 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 8 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,951.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 940 | $166.54 | $156,547.60 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 7 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,716.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 1,380 | $166.53 | $229,811.40 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 6 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,656.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 2,183 | $166.52 | $363,513.16 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 5 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,036.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 725 | $166.51 | $120,719.75 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 4 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,219.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 100 | $166.50 | $16,650.04 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 3 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,944.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 6,611 | $166.50 | $1,100,731.50 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,044.1875 Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:34 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 19,061 | $142.94 | $2,724,579.34 |
DisclosureSEC source: 0000066740-25-000096 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,655.1875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:57 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 3,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004705 · form4.xml · derivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,381 Underlying: Common Stock · 3,381 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F3 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date. F3 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:57 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,235 | $0.00 Strike: $148.87 | $0.00 |
DisclosureSEC source: 0001127602-25-004705 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,235 Underlying: Common Stock · 15,235 shares Expires 2035-02-11 F1 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 13:34 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionRestricted Stock Units · Derivative | 2,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003696 · form4.xml · derivative · entry 3 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F3 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date of February 8, 2022 F3 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date of February 8, 2022 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 13:34 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 942 | $149.87 | $141,177.54 |
DisclosureSEC source: 0001127602-25-003696 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,479.8998 F1 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 13:34 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 2,974 | $149.87 | $445,713.38 |
DisclosureSEC source: 0001127602-25-003696 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,421.8998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:54 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003127 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447.8998 F2 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary. F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:54 UTC | 3M CO MMM · Entity 1275 | GrantCommon Stock | 3,251.227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003127 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,442.8998 F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 1, 2022. The performance-based vesting requirements applicable to such awards were satisfied on the date reported in Column 2, which represents the date on which the level of performance attained was certified. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:05 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionRestricted Stock Units · Derivative | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026331 · form4.xml · derivative · entry 3 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F3 · derivative.exercise_date: The restricted stock units vest three years from the grant date. F3 · derivative.expiration_date: The restricted stock units vest three years from the grant date. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:05 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 646 | $127.22 | $82,184.12 |
DisclosureSEC source: 0001127602-24-026331 · form4.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,131.2846 Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:05 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 2,111 | $127.22 | $268,561.42 |
DisclosureSEC source: 0001127602-24-026331 · form4.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,777.2846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares originally reported were adjusted due to the spin-off of Solventum, the Company's healthcare business group, on April 1, 2024. Read SEC document |
| May 03, 2024 Filed May 6, 2024 22:43 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 11,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014340 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,992 Underlying: Common Stock · 11,992 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 6, 2027. F2 · derivative.expiration_date: The restricted stock units vest on February 6, 2027. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:03 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004031 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,828 Underlying: Common Stock · 7,828 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F2 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date of February 7, 2023. F2 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date of February 7, 2023. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:39 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 2,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004045 · form4.xml · derivative · entry 2 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,617 Underlying: Common Stock · 2,617 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F3 · derivative.exercise_date: The restricted stock units vest 100% three years from the grant date of February 8, 2022 F3 · derivative.expiration_date: The restricted stock units vest 100% three years from the grant date of February 8, 2022 Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:39 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 16,775 | $0.00 Strike: $162.41 | $0.00 |
DisclosureSEC source: 0001127602-22-004045 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · EVP & Chief Info Digital Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,775 Underlying: Common Stock · 16,775 shares Expires 2032-02-06 F1 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:55 UTC | 3M CO MMM · Entity 1275 | GrantRestricted Stock Units · Derivative | 1,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-028256 · form4.xml · derivative · entry 1 Murphy Mark W. · CIK 0001575293 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,857 Underlying: Common Stock · 1,857 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of 3M common stock. F2 · derivative.exercise_date: The restricted stock units vest three years from the grant date. F2 · derivative.expiration_date: The restricted stock units vest three years from the grant date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 1,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 11 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,905 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 23,936 | Not disclosed Strike: $61.62 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 10 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,936 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 1,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 9 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,114 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 19,616 | Not disclosed Strike: $69.08 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 8 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,616 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 7 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.